>>> Merck reports EPS in-line, misses on revs; guides FY17 below consensus

Merck reports EPS in-line, misses on revs; guides FY17 below consensus
  • Reports Q4 (Dec) earnings of $0.89 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of $0.89; revenues fell 1.0% year/year to $10.12 bln vs the $10.23 bln Capital IQ Consensus, including a 1 percent negative impact from FX. Sales in the fourth quarter of 2016 reflect the unfavorable impact of ~$150 million of sales in Japan, which occurred in the third quarter of 2016 rather than in the fourth quarter due to the implementation of a resource planning system.
  • Q4 pharmaceutical sales decreased 1 percent to $8.9 billion. The decline was driven primarily by the loss of U.S. market exclusivity in 2016 for CUBICIN (daptomycin for injection), an I.V. antibiotic; NASONEX (mometasone furoate monohydrate), an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms; and ZETIA (ezetimibe), a medicine for lowering LDL cholesterol; as well as by the ongoing impact of biosimilar competition in the company's marketing territories in Europe for REMICADE (infliximab), a treatment for inflammatory diseases. In the aggregate, sales of these products declined $564 million during Q4 compared to the fourth quarter of 2015.
  • These declines were largely offset by growth in oncology, hepatitis C, diabetes and vaccines, which include the ongoing launches of KEYTRUDA and ZEPATIER (elbasvir and grazoprevir), a medicine for the treatment of chronic hepatitis C virus genotypes 1 or 4 infection. Additionally, the ongoing launch of BRIDION (sugammadex) Injection 100 mg/mL, a medicine for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults undergoing surgery, generated sales of $139 million during the fourth quarter of 2016.
  • Growth of KEYTRUDA reflects the company's continued efforts to launch the product with new indications, particularly as a first-line treatment for NSCLC and for previously treated recurrent or metastatic head and neck cancer in the United States, and as a second-line treatment for NSCLC globally.
  • Januvia/Janumet +4% to $1.5 bln; Zetia/Vytorin 13% to $873 bln; Gardasil +9% to 542 mln; Keytruda +125% to $483 mln
  • Co issues downside guidance for FY17, sees EPS of $3.72-3.87, excluding non-recurring items, vs. $3.87 Capital IQ Consensus Estimate; sees FY17 revs of $38.6-40.1 bln vs. $40.19 bln Capital IQ Consensus Estimate.

>>> Estee Lauder beats by $0.05, misses on revs; guides Q3 EPS, revs below conse


Estee Lauder beats by $0.05, misses on revs; guides Q3 EPS, revs below consensus; lowers FY17 EPS, revs guidance
  • Reports Q2 (Dec) earnings of $1.22 per share, $0.05 better than the Capital IQ Consensus of $1.17; revenues rose 2.7% year/year to $3.21 bln vs the $3.24 bln Capital IQ Consensus.
  • Co issues downside guidance for Q3, sees EPS of $0.65-0.70 vs. $0.84 Capital IQ Consensus Estimate; sees Q3 revs of ~$2.79-2.82 bln (+5-6%) vs. $2.9 bln Capital IQ Consensus Estimate.
  • Co lowers guidance for FY17, sees EPS of $3.29-3.33 (Prior $3.38-3.44) vs. $3.39 Capital IQ Consensus Estimate; sees FY17 revs of ~$11.71-11.83 bln (+4-5%) (Prior +6-7%) vs. $11.88 bln Capital IQ Consensus Estimate. Foreign currency translation is expected to negatively impact sales by approximately 2% versus the prior-year period (Previously expected foreign currency translation to negatively impact sales by less than 1% versus the prior-year period)
  • The Company expects to take charges associated with previously approved restructuring and other activities in fiscal 2017 of approximately $110 million to $130 million, equal to $.19 to $.22 per diluted common share.
  • "We expect sales and profit growth to further accelerate in the second half of our fiscal year, due largely to strong product innovation, increased consumer coverage and improving trends in certain brands and markets. We plan to make targeted investments throughout the balance of the fiscal year to support and grow our brands. With our plans in place, we expect 2017 fiscal year constant currency sales growth of 6% to 7%, which includes approximately 1% of incremental sales attributable to the recent acquisition of Too Faced. We now expect constant currency earnings per share growth of 8% to 9%, before charges, which reflects $.04 of dilution related to Too Faced."

NY Post : Macy’s sale rumored as long-time CEO steps down

Terry Lundgren’s final weeks as chief executive of Macy’s are anything but peaceful.

The veteran retail boss, who is stepping down as CEO later in the quarter, is trying to avoid an ugly board shakeup that could tarnish his 13-year legacy and turn the largest US department store into a battleground littered with discarded top brass, The Post has learned.

Lundgren, who had not planned to cap his tenure with a sale, has recently become open to offers from potential friendly buyers as a proactive measure to head off any attempt to mess with the board, sources familiar with the situation said.

A partner at a private equity firm told The Post that he’d been contacted about a Macy’s sale by a real estate investor — while other industry sources close to the situation say they, too, have had similar discussions.

“We do not comment on rumors and speculation,” a Macy’s spokesperson told The Post.

The catalyst, it seems, is Jeffrey Smith’s Starboard Value, the activist New York hedge fund. Smith is said to be fed up with Macy’s poor performance since he invested in it in July 2015. Macy’s shares are down nearly 60 percent since then.

Smith is angling for seats on Macy’s board, according to several sources, who describe the situation as a looming proxy battle in advance of Macy’s annual meeting, which will likely take place in late April or May.

Starboard didn’t return calls, but it’s no secret that it has pushed Macy’s to unlock the value in its real estate holdings: Macy’s owns approximately 50 percent of its 880 stores.

Last year, Macy’s added William Lenehan, CEO of Four Corners Property Trust — a REIT — to its board.

The retailer also hired a real estate executive to negotiate with developers — and then it struck a deal with Brookfield Asset Management to redevelop about 50 Macy’s stores.

Starboard has said that Macy’s real estate is worth about $21 billion. Its market cap sits at about $9 billion.

With Macy’s annual meeting coming up and Jeff Gennette set to take over as CEO, Lundgren wants to shore up Macy’s future.

Lundgren, 65, has agreed to stay on as chairman.

>>> Ferrari beats by EUR 0.16, beats on revs; guides FY17 revs in-line (62.14)

Ferrari beats by EUR 0.16, beats on revs; guides FY17 revs in-line
  • Reports Q4 (Dec) earnings of €0.69 per share, excluding non-recurring items, €0.16 better than the Capital IQ Consensus of €0.53; revenues rose 12.4% year/year to €836 mln vs the €819.87 mln Capital IQ Consensus. Shipments -4% to 1940.
  • Co issues in-line guidance for FY17, sees FY17 revs of > EUR 3.3 bln vs. €3.31 bln Capital IQ Consensus. Shipments: ~ 8,400 including supercars; Adjusted EBITDA: > Euro 950 million; Net industrial debt: ~ Euro 500 million, including a cash distribution to the holders of common shares and excluding potential share repurchases.

>>> Eaton beats by $0.02, reports revs in-line; guides Q1 EPS below consensus; g

Eaton beats by $0.02, reports revs in-line; guides Q1 EPS below consensus; guides FY17 EPS in-line with midpoint above consensus (71.31)
  • Reports Q4 (Dec) earnings of $1.12 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $1.10; revenues fell 3.8% year/year to $4.87 bln vs the $4.91 bln Capital IQ Consensus. The sales decrease consisted of 3 percent from a decline in organic sales and 1 percent from negative currency translation.
  • "Our fourth quarter net income and operating earnings per share were above the midpoint of our guidance despite fourth quarter sales coming in 1 percent lower than our expectations. The shortfall in sales resulted solely from higher negative currency translation due to the rise in the U.S. dollar following the U.S. election. Our organic sales for the quarter came in slightly better than expected, and some segments showed modestly improved order trends.
  • Co issues downside guidance for Q1, sees EPS of $0.80-0.90 vs. $0.90 Capital IQ Consensus Estimate.
  • Co issues in-line guidance for FY17, sees EPS of $4.30-4.60 vs. $4.37 Capital IQ Consensus, representing a 6 percent increase at the midpoint of our guidance in net income per share over 2016 and a 5 percent increase at the midpoint of our guidance in operating earnings per share over 2016," said Arnold. "Our guidance is based on flat organic revenue and negative currency translation of $300 million.

>>> Boston Scientific beats by $0.01, beats on revs; guides Q1 EPS in-line, revs

Boston Scientific beats by $0.01, beats on revs; guides Q1 EPS in-line, revs in-line; guides FY17 EPS in-line, revs in-line

  • Reports Q4 (Dec) earnings of $0.30 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.29; revenues rose 10.8% year/year to $2.19 bln vs the $2.16 bln Capital IQ Consensus. Grew organic revenue 10 percent in the fourth quarter over the prior year period. Organic revenue growth excludes the impact of changes in foreign currency exchange rates and sales from the acquisition of EndoChoice Holdings, Inc. (EndoChoice).
    • Achieved excellent fourth quarter revenue growth in all segments, all compared to the prior year period: Medsurg: 13 percent (12 percent operational and 11 percent organic) Cardiovascular: 11 percent reported, operational and organic Rhythm Management: 7 percent reported, operational and organic
    • Delivered revenue growth in all regions, all compared to the prior year period
  • Co issues in-line guidance for Q1, sees EPS of $0.29-0.31, excluding non-recurring items, vs. $0.29 Capital IQ Consensus Estimate; sees Q1 revs of $2.05-2.10 bln vs. $2.08 bln Capital IQ Consensus Estimate.
  • Co issues in-line guidance for FY17, sees EPS of $1.22-1.26, excluding non-recurring items, vs. $1.26 Capital IQ Consensus Estimate; sees FY17 revs of $8.675-8.875 bln vs. $8.8 bln Capital IQ Consensus Estimate.

(ZH) With The Greek Crisis Back, There Are Five Possible Scenarios From Here

With The Greek Crisis Back, There Are Five Possible Scenarios From Here

As discussed last Friday, Greece is back in the public spotlight and - hardly surprising - it is once again on the verge of collapse. Greek yields surged in the past week as the country didn’t secure a positive review at the Eurogroup on 26 January. Additional noise came from indications that the IMF still views the Greek debt as unsustainable without further measures from the Greek government (the term was "explosive"), as well as additional debt relief clarifications from European creditors.

So is a rerun of the summer of 2015 inevitable? According to Credit Suisse's Giovanni Zanni, the most likely outcome - for now- is an amicable, and quick, resolution. However the longer nothing substantive changes, the more likely it is that the 4, far less pleasant scenarios, kick in.
While it is difficult to attribute a specific probability to each of those, they are ranked them below by the most to the least likely. These scenarios should also provide a roadmap for investors in the process of assessing when risks could increase and when they could die down: as a rule of thumb, we would expect a sell-off to be ongoing until the next “node”, unless the tension is released by some form of agreement, which we still believe will come at some point in the coming months. In the absence of any deal, market stress is likely to steadily increase ahead of large Greek bond redemptions, in particular those in late July, with a calendar pretty similar to that of 2015. But while we expected at the time that a solution would have come very late in the game (in July, precisely), this time the base case scenario is for a quicker resolution.
Here are the five possible scenarios from the Swiss bank:
  • Scenario 1:Quick resolution (in the coming days)
The Greek government is reportedly trying to find an agreement, providing a series of measures that should be largely compliant with the creditors’ requests and are crafted in a way that should be sufficient to convince the IMF to agree to continued participation in the programme. There is a key IMF meeting on 6 February: if the measures are accepted then it should open the way for a successful completion of the review on 20 February by the Eurogroup. This, in our view, would also set in motion a clarification of the medium-term relief measures (after 2018) to be granted, conditionally, to Greece. And from there the Debt Sustainability Analysis of both the IMF and the ECB should reinforce Greece’s position and allow the European Central Bank to include GGBs in its QE program.
That is clearly the positive scenario – and the most optimistic in the timing (e.g., it might still happen as above, broadly speaking, but delayed by a few days or weeks, clearly) – but we still think it can happen, with a decent probability. This would lead in all likelihood to a prompt reversal of the spread widening seen in recent weeks, and to further convergence ahead – especially if and when the participation of GGBs in ECB’s QE is announced.
The other four (less positive to outright negative) scenarios are discussed overleaf.
  • Scenario 2: “We need more time” (March-April)
There is a fundamental “irreconcilable trinity” between the views of the IMF, that of European creditors and those of the Greek government: at the cost of oversimplifying, Greeks want less reform, more debt relief, and would prefer a lower primary surplus target; the IMF would like more structural reforms, more debt relief from European creditors, and lower primary surpluses – expecting Greece to deliver primary surpluses at 3.5% of GDP for the foreseeable future is seen as unrealistic; finally, European creditors are relatively agnostic on reforms, want ideally as little debt relief as possible, and prefer higher primary surpluses to fill the debt sustainability gap. It is not clear that these differences can be resolved, effortlessly, in a short period of time – it might still require a further layer of negotiations and developments. Still, there is some kind of “political imperative”, we believe, with indeed the preference by all to close the negotiations ahead of at least the French elections, in order not to poison further the European political debate. As such, a decision might eventually be pushed through next month or in April, at the latest, if disagreements are not too extreme.
  • Scenario 3: brinkmanship (July)

This scenario would mimic the events of 2015, when the confrontation was pushed to the limit of default from the Greek side, in the hope of getting the best possible deal. In our view, that strategy didn’t work for Greece and created uncertainty and another recession in that year. As such, we struggle to see this strategy as intentional this time – but it could end up being the default option in the absence of an agreement under scenarios 1 and 2 and in the context of elections and events in the rest of Europe diverting the focus on Greek matters.
  • Scenario 4: Early elections (before the summer)
Early elections cannot be discarded, if a satisfactory agreement is not found in the coming two to three months. It is likely that most MPs dislike this option, as early elections would likely see several in the majority losing their seats: current polls suggest a very strong preference for the center-right opposition (New Democracy), as we show in Figure 6. However, it would be a way to preserve an “anti-system” role to the ruling party, Syriza, with the aim and hope to return in government at a (not too) later stage, in a new election round. From a market perspective, early elections would clearly be a negative, short term, but we also stress that the likely victory of the centre-right would be probably seen as a positive medium-term outcome.
  • Scenario 5: Grexit? Oh pleeease!
SYRIZA parliamentary spokesman Nikos Xydakis said earlier this week that a debate about Greece’s membership of the euro should not be taboo, seemingly reopening the discussion on Greece’s EU membership. We have debated this issue at length in the past, and believe it wouldn’t make sense for Greece to leave – and actually it is already damaging for the country to even discuss it. The opposition was quick in criticising Mr Xydakis and there is clearly no support in the parliament for it and even less so in the country (Figure 7).
* * *
Finally, here is a timeline of next events:
Below, we provide a timeline of key relevant dates and events in the coming months. There is an immediate set of events (in February) that could resolve the issues and make the programme progress swiftly. If not in February, there are several intermediate dates that could still deliver an agreement, although at a later stage, most likely around the scheduled Eurogroup meetings – although an extraordinary gathering to approve the bailout happened in the past and cannot be discarded. July 17 – or 20 – would be the “hard” deadline, as Greece would be, same as in July 2015, unable to repay those amounts without additional support under the EU/IMF programme. There are earlier relatively large redemptions, notably in late February and in April – but we believe there is probably room in Greece’s public finances to fulfill those commitments.

>>> Immofinanz intends to sell 4.5m ordinary shares in BUWOG

Immofinanz intends to sell 4.5m ordinary shares in BUWOG
01 FEB 2017
IMMOFINANZ, the Austria-based real estate company, today announced its intention to sell approximately 4.5m ordinary shares in domestic entity BUWOG, representing 4.5% of the issued share capital at the target.
Proceeds of the sale will be used to optimize the overall cost of debt at IMMOFINANZ and for general corporate purposes. After the transaction IMMOFINANZ is expected to hold approximately 4.7m BUWOG shares.

Press Release:
IMMOFINANZ announced its intention to sell approximately 4.5m ordinary shares (the "Placing Shares") in BUWOG AG (the "Company"). The Placing Shares represent approximately 4.5% of the Company's issued share capital.
The sale is part of the strategic reduction of IMMOFINANZ’ shareholding in BUWOG AG. The proceeds of the sale will be used to optimize the overall cost of debt of IMMOFINANZ and for general corporate purposes.
The Placing Shares are being offered by way of an accelerated bookbuilding (the "Placement") to institutional investors, which will be launched immediately following this announcement.
The final number of Placing Shares to be placed will be determined at the closing of the bookbuilding process, and the results of the Placement will be announced as soon as practicable thereafter.
After the transaction IMMOFINANZ is expected to hold 4.7m BUWOG shares which serve as an underlying for the convertible bonds 2017 and 2018.